Pharmacogenomics (PGx) Pain Panel
A 7-gene pharmacogenomic panel for optimizing pain management drugs including NSAIDs, opioids, tranquilizers, and tricyclic antidepressants, powered by the Helix Exome+® platform.
6-9 days
≤ 5 minutes
Panel Description
Many pain medications are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.
This panel evaluates 7 genes associated with response to drugs prescribed to treat pain, including NSAIDs, opioids, tranquilizers, and tricyclic antidepressants. Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs.
Have Questions?
Our team is available Monday through Friday, 9am-5pm Pacific Time.
Indications for Testing
Patients for whom pain medications are being considered, have been ineffective or caused side effects.
Methodology
This test utilizes next-generation sequencing to determine results for COMT, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and OPRM1.
Technical Specifications
COMT: rs4680; CYP2C9: *1-*61; CYP2C19: *1-*19, *22-*26, *28-*39; CYP2D6: *1-*15, *4N, *17-*65, *68-*75, *81, *83-*114; CYP3A4: *1-*24, *26, *28-*38; CYP3A5: *1, *3, *6-*9; OPRM1: rs1799971...
Sensitivity may be reduced for the CYP2D6*13 allele.
Genes Tested
Showing 7 of 7 genes in this panel